Movement Alert|SPYRE THERAPEUTICS Falls 10.83% in Pre-Market Trading, Trading at $86.54

Market Focus
06/24

On June 24, SPYRE THERAPEUTICS fell 10.83% in pre-market trading, trading at $86.54 USD/share, with Turnover of $17,500.

Within the Biotechnology sector where SPYRE THERAPEUTICS belongs, individual stock performance was mixed. Among individual stocks, Apogee Therapeutics up 1.44%, AbbVie up 0.63%, Regeneron Pharmaceuticals up 0%, Gilead Sciences down 0.14%, Amgen down 0.58%.

SPYRE THERAPEUTICS is a preclinical stage biotechnology company focused on developing therapeutics for patients with inflammatory bowel disease (IBD). Its product pipeline includes SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23), along with combination therapies SPY120, SPY130, and SPY230.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10